Nadia Cherradi

Dr. Nadia Cherradi

INSERM U1292 - Biology and Biotechnologies for Health
+2
orcid

Biography

A tight link between dysregulations in mRNA decay mechanisms and cancer hallmarks is now clearly established. Notably, abnormal stabilization of transcripts encoding pro-tumoral cytokines, chemokines or proto-oncogenes occurs during tumor development and progression. My research aims at deciphering the mechanisms involved in such dysregulations and focus on 2 key players in the control of mRNA fate: the Tristetraprolin zinc finger proteins TTP/ZFP36 and Tis11b/ZFP36L1, and microRNAs. I am using an integrative approach combining cellular and molecular biology, preclinical models and translational/clinical studies. The research program runs along 3 complementary axes: 1) the study of the molecular mechanisms through which TTP proteins and microRNAs regulate mRNA decay in normal and cancer cells; 2) the search for alterations in mRNA stability regulators (TTP proteins and microRNAs) in adrenocortical cancer and their evaluation as potential diagnostic/prognostic biomarkers; 3) the development of preclinical anti-cancer therapies targeting mRNA stability regulators in adrenocortical cancer.

Affiliations

No affiliation has been shared yet.

Honors and Awards

honor

Riotton Pharmaceutical Award

Faculty of Medicine of Geneva

Geneva, Switzerland, 1997

honor

Mara E. Lieberman Award

Endocrine Society

Toronto, Canada, 2000

honor

Searle Young Investigator Award

Aldosterone Conference

Toronto, Canada 2000

honor

Servier Pharmaceutical Award

Swiss Endocrine Society

Bern, Switzerland, 2002

honor

National Research Program in Reproduction and Endocrinology

INSERM

Grenoble, France, 2007

honor

National Program in Translational Research (Contrat Hospitalier de Recherche Translationnelle)

INSERM

Grenoble, France 2010-2013

Experience

No experience has been shared yet.